Bank of America Securities is cautioning that Fiserv's upcoming third-quarter earnings report, scheduled for November 3rd, could test investors' patience. In a research note, the investment bank said it expects "uninspiring" results, including adjusted earnings per share of $1.68, as the payments giant works through a slower-than-expected recovery from last quarter's growth slowdown.
Fiserv, a major provider of financial services technology, has been a staple in many investors' portfolios for its steady, recurring revenue. But the company is now in the middle of what BofA describes as a "multi-year cleanup" — rebuilding client trust, tightening day-to-day execution, and defending its competitive position. The bank argues that Fiserv's mix of businesses may generate fewer cost savings and cross-selling benefits than investors hope, making the turnaround longer and more uneven than the market anticipates.
Clover: The Key to the Story
A significant portion of the concern centers on Clover, Fiserv's payment terminal and software offering for merchants. Clover is central to Fiserv's longer-term growth narrative, but BofA expects its revenue to rise just 2.4% in the quarter. That's a modest gain, especially as point-of-sale rivals become more aggressive, making it harder for Fiserv to win market share and convert new customers into recurring revenue.
For everyday investors, Clover is more than just a product line — it's a bellwether for Fiserv's ability to compete in the fast-evolving payments space. If Clover struggles, it could signal broader challenges for the company's growth engine.
What BofA's Numbers Imply
BofA reinstated coverage on Fiserv with an underperform rating and a $48 price target, even though the stock is currently trading around $46.95. The bank also set its fiscal 2026 earnings per share estimate at $7.14, suggesting the recovery path could be bumpy.
Doing the math on BofA's view reveals a key tension: $48 divided by $7.14 is roughly 6.7 times earnings. That's a low valuation for a large payments company — if growth re-accelerates, the stock could look cheap. But if Clover remains sluggish and competitive pressure persists, that multiple might be justified.
When Wall Street starts framing a turnaround as "multi-year," the debate often shifts from next quarter's profit to how much investors are willing to pay for profits several years out. In other words, the risk shows up in the valuation multiple — the price-to-earnings ratio — before it shows up in the earnings estimate.
What to Watch on November 3rd
The November 3rd report may matter less for whether Fiserv beats consensus by a few cents and more for whether management can credibly shorten the timeline to healthier Clover growth and steadier execution. Investors will be listening for any signs that the competitive pressure on Clover is easing, or that the company's cost-saving initiatives are starting to bear fruit.
For those holding Fiserv shares, the key takeaway is that the stock's valuation could remain under pressure until there's clear evidence of a turnaround. As BofA's note suggests, patience may be required — and the market's patience is often in short supply.
This isn't the only company facing a test of investor patience this earnings season. Domino's order growth held up, but its store openings slowed, showing that even growth stories can have weak spots. Similarly, UBS sees Diageo's organic sales growth ahead of its November update, highlighting how analysts are scrutinizing companies' ability to maintain momentum.
For investors, the broader lesson is that when a company embarks on a multi-year turnaround, the market's focus shifts from short-term earnings beats to the long-term trajectory. That can make for a volatile ride, as the stock price reacts to every piece of news about the company's progress.
In the meantime, Fiserv investors will be watching closely to see if the company can deliver a credible plan to revive Clover's growth and restore confidence in its execution. Until then, the stock may continue to trade at a discount, reflecting the market's uncertainty about the path ahead.
